IP Library Granted Patent US 9,650,383
Granted Patent B2
US 9,650,383 · App. 14/541,365 · Granted May 16, 2017

Aldose reductase inhibitors and uses thereof

Inventors: Andrew Wasmuth (New York, NY); Donald W. Landry (New York, NY); Shi Xian Deng (White Plains, NY); Banavara L. Mylari (East Lyme, CT); Ravichandran Ramasamy (Ardsley, NY); Ann Marie Schmidt (Franklin Lakes, NJ)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,383
App. No.
14/541,365
Granted
May 16, 2017
Kind
B2
Abstract

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.

Claims (60)

1. A method of treating a subject with evolving myocardial infarction comprising: administering a therapeutically effective amount of a compound of formula (I)

wherein,

R 1 is H;

X 1 is N;

X 2 is CH;

X 3 is CH;

X 4 is N ;

Y is a C═O, C═S, C═NH, or C═N(C 1 C 4 )-alkyl;

Z is

A 1 is S;

A 2 is N; and

R 7 through R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl; or two of R 7 through R 10 taken together are (C 1 -C 4 )-alkylenedioxy;

or a pharmaceutically acceptable salt or solvate thereof;

to a subject in need thereof.

2. The method of claim 1 , wherein

Y is C═O; and

R 7 through R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl.

3. The method of claim 2 , wherein

R 7 through R 10 are independently hydrogen, halogen, or haloalkyl.

4. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound of formula (I) is

6. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt or solvate thereof.

7. The method of claim 1 , wherein the compound of formula (I) is

8. The method of claim 1 , wherein the subject is a human.

9. The method of claim 4 , wherein the subject is a human.

10. The method of claim 5 , wherein the subject is a human.

11. A method of treating a subject with evolving myocardial infarction comprising: administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I)

wherein,

R 1 is H;

X 1 is N;

X 2 is CH;

X 3 is CH;

X 4 is N;

Y is a C═O, C═S, C═NH, or C═N(C 1 -C 4 )-alkyl;

Z is

A 1 is S;

A 2 is N; and

R 7 through R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl; or two of R 7 through R 10 taken together are (C 1 -C 4 )-alkylenedioxy;

or a pharmaceutically acceptable salt or solvate thereof; and

a pharmaceutically acceptable carrier, to a subject in need thereof.

12. The method of claim 11 , wherein

Y is C═O; and

R 7 through R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl.

13. The method of claim 12 , wherein

R 7 through R 10 are independently hydrogen, halogen, or haloalkyl.

14. The method of claim 11 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt thereof.

15. The method of claim 11 , wherein the compound of formula (I) is

16. The method of claim 11 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt or solvate thereof.

17. The method of claim 11 , wherein the compound of formula (I) is

18. The method of claim 11 , wherein the subject is a human.

19. The method of claim 14 , wherein the subject is a human.

20. The method of claim 15 , wherein the subject is a human.

21. The method of claim 6 , wherein the subject is a human.

22. The method of claim 7 , wherein the subject is a human.

23. The method of claim 16 , wherein the subject is a human.

24. The method of claim 17 , wherein the subject is a human.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 8, 2020
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054032/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2015
From: WASMUTH, ANDREW; LANDRY, DONALD W; DENG, SHIXIAN; RAMASAMY, RAVICHANDRAN; SCHMIDT, ANN-MARIE; MYLARI, BANAVARA L
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 035243/0388 →
Continuity (4)
Division 13742573 · Jan 16, 2013
Continuation In Part PCTUS2011044038 · Jul 14, 2011
Provisional Application 61365098 · Jul 16, 2010
Related Publication 20150072989A1 · Mar 12, 2015